Európska únia - lotyština - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridīns - multiplā skleroze - other nervous system drugs - fampyra tiek norādīts uzlabošanas pieaugušiem pacientiem ar multiplo sklerozi iešana ar kājām invaliditātes (paplašināts invaliditātes statusa skalas 4-7).

Európska únia - lotyština - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistiskā fibroze - other respiratory system products - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 un 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 un 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Európska únia - lotyština - EMA (European Medicines Agency)

biogen netherlands b.v. - zinersens nātrijs - muskuļu atrofija, mugurkaula - other nervous system drugs - par attieksmi pret 5q muguras muskuļu atrofija ir norādīts spinraza.

Lotyšsko - lotyština - Zāļu valsts aģentūra

pharmathen s.a., greece - klopidogrels - apvalkotā tablete - 75 mg

Lotyšsko - lotyština - Zāļu valsts aģentūra

teva b.v., netherlands - dorzolamidum, timololum - acu pilieni, šķīdums - 20 mg/5 mg/ml

Európska únia - lotyština - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - muskuļu atrofija, mugurkaula - other drugs for disorders of the musculo-skeletal system - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Európska únia - lotyština - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - other nervous system drugs - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Európska únia - lotyština - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - imūnsupresanti - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Európska únia - lotyština - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - other nervous system drugs - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Európska únia - lotyština - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - cukura diabēts - cukura diabēts - cukura diabēts, ja nepieciešama insulīna terapija. insuman rapid ir arī piemērota hyperglycaemic koma un ketoacidosis ārstēšanai, kā arī panāktu, iepriekšēja, intra - un pēcoperācijas stabilizācijas pacientiem ar cukura diabētu.